{"name":"Cipla","slug":"cipla","ticker":"CIPLA.NS","exchange":"NSE","domain":"cipla.com","description":"Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.","hq":"Mumbai, India","founded":0,"employees":"30313","ceo":"Umang Vohra","sector":"Respiratory / Anti-Retrovirals / Generics","stockPrice":1215.9,"stockChange":13.5,"stockChangePercent":1.12,"marketCap":"$982.2B","metrics":{"revenue":279671898112,"revenueGrowth":0,"grossMargin":65.2,"rdSpend":0,"netIncome":45464301568,"cash":106022404096,"dividendYield":1.08,"peRatio":21.6,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Tasigna","genericName":"NILOTINIB","slug":"nilotinib","revenue":400000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2007-01-01","label":"Tasigna first approved","drug":"Tasigna","drugSlug":"nilotinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Triomune patent cliff ($100MB at risk)","drug":"Triomune","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Asthalin patent cliff ($50MB at risk)","drug":"Asthalin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":400000000,"percentOfTotal":100,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Tasigna","genericName":"NILOTINIB","slug":"nilotinib","indication":"Chronic Myelocytic Leukemia Accelerated Phase","status":"marketed","revenue":400000000},{"name":"EU-sourced Avastin®","genericName":"EU-sourced Avastin®","slug":"eu-sourced-avastin","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CBT124","genericName":"CBT124","slug":"cbt124","indication":"unknown","status":"phase_3"}]}],"pipeline":[{"name":"Tasigna","genericName":"NILOTINIB","slug":"nilotinib","phase":"marketed","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML.","indications":["Chronic Myelocytic Leukemia Accelerated Phase","Chronic phase chronic myeloid leukemia","Philadelphia Chromosome Positive Chronic Myelocytic Leukemia"],"catalyst":""},{"name":"CBT124","genericName":"CBT124","slug":"cbt124","phase":"phase_3","mechanism":"CBT124 is a small molecule that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"EU-sourced Avastin®","genericName":"EU-sourced Avastin®","slug":"eu-sourced-avastin","phase":"phase_3","mechanism":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Cipla reports 12% rise in Q3 net profit","summary":"Cipla's net profit rose 12% to ₹1,144 crore in the third quarter of the fiscal year 2023-24, driven by strong sales growth in emerging markets.","drugName":"","sentiment":"positive"},{"date":"2023-11-21","type":"deal","headline":"Cipla acquires US-based InnoPharma for $35 million","summary":"Cipla has acquired US-based InnoPharma, a specialty pharmaceutical company, for $35 million. The acquisition will help Cipla expand its presence in the US market.","drugName":"","sentiment":"positive"},{"date":"2023-08-22","type":"regulatory","headline":"Cipla receives US FDA approval for generic version of asthma medication","summary":"Cipla has received US FDA approval for its generic version of the asthma medication Symbicort. The approval will help Cipla expand its presence in the US market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWFFtUFhPeDlDckF1ZDNTcURfWUUwYWxuLTF2azRGd2o4V09xLUF3bDk2dVhUcnN2MWZEd3JHbEllTkZPLWt1WktWVDVvdnBlTzFjbmR0QndyRTZqaE5uZ3MySFNBems3LWI3MTczMHZhVkV2amM3TTZxSnVMVVlRUUNFWDdXbTdCNS0wMUpKSTV1dHBwOC1nZUtaUEtpUE9yRVU2dzFDeG5xUQ?oc=5","date":"2026-04-03","type":"regulatory","source":"Yahoo Finance","summary":"Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis - Yahoo Finance","headline":"Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary F","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTlphMUphemxGZjMycXRGTXoweExKeW1EOVc0Ynd1d1MzSUZURVo5Zk9yck1MY0NGb3FZMURRZGs1UUZ5T1ZNUXFoQUh2dk9Vemk1OVZUMGhmb0pFc2tJbW8tOGpIaVhIV19IS3o0MGhVWmVkVS1neEtMVDJCVzhUcEZES3pLajV3aFFr?oc=5","date":"2026-02-27","type":"patent","source":"Yahoo Finance","summary":"Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy - Yahoo Finance","headline":"Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPUDRXUVlpX2ROTlNHem9WMmxpdmQ3OGhMLXJxOE9ZSW00ZWJiVjVDeldybmcxMklEZkU0aUQzcXNsWmhFU1ZxMklweV9fVENaTnY2VVlTMWxaa0ZtNU85Zl8ybjlRRUo0ekI4cFdCLXl5ejRuM2xyYmdRRmJZT3dfWktlcXZXLWlUNXNWcA?oc=5","date":"2026-01-23","type":"earnings","source":"Yahoo Finance Singapore","summary":"India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch - Yahoo Finance Singapore","headline":"India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPODZLenRLbGRJcE5ydXFPNlplbjUxYTMtcnJBUlVwdHJ5WDdPaWVUNG1UNHozUE1nZ3JTeDRIMXV3TG1CcGI2ZEhteUdJRlBqYlJrMm9UMi1ISDdxOFBxYkpGM2E3cUJEZUJlTWotSVZCYzJBdFIyaDM3LW5sUEwwR2hCaUUyVXAtWkNwQW1SbkwzOHVoZkNuNzVfUGdNejRGSTFrNEoyaTFubG9ZazI1SE9FRGwxWHVTQW85S0xR?oc=5","date":"2025-11-09","type":"pipeline","source":"reuters.com","summary":"Novo Nordisk, Emcure to launch weight-loss drug under new brand in India - reuters.com","headline":"Novo Nordisk, Emcure to launch weight-loss drug under new brand in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOMFduR0dmdW5kUWlta2lsUzMzelZtaFg2U3hUWWJnUDJaMkZubEc3WGY5MGQwZ01wTVo4bWZ4RWhnUFJMMDNRSzFDaUUwQzhpcC1BTDZTcjdzZnNwM1lwbGpuZ0dvWGtNVng4QlpzbHlJaFFhU3hWQTY3cWEwbC1MR01UempacDBk?oc=5","date":"2025-08-07","type":"pipeline","source":"Yahoo Finance","summary":"Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles - Yahoo Finance","headline":"Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOR1BuT0hrZFNod1VSR3h4bnMwME84V2Z5aTJyM2NyaC1ad2NSOTVzRzB6UldLNnlWaTNfcHlZUmpmamVtRW1nVkFTcUhfNUQ2QmJZZWV5aTVtbmVNUlVUVS1wWkcxVENWV2N4RW5tS1JXVzA2djdfUGJLVFllYWhKZHRibWhvNVdHa1JYcG9hOTVxT3YwSFd1V1ZDMkpmc2lsU2s0RDQ3RWw3cXdTWmlkZ1ZkR2d2NlUzT0xscHpuOUVnVXlDTVJlRFF2eVJkYjU2LWJrZGNpUU4zTDdYbDFPQg?oc=5","date":"2025-02-28","type":"pipeline","source":"reuters.com","summary":"Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says - reuters.com","headline":"Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPZWZBeFdlT3BCNm9GNnpINUt4TGdOU0Q5R0VZSzkzLTlLSlJPRUpETm9CdGQ2R1F0WEphZWlvOUZCMmg2Um5wb2Z4WUt4WWFicVZ4ZTQyUFJBVjh5VU5qMXI0VTFWUlh6ekNuTkJ5RVNKUGsyQ3RMelAwQUxmUHVYTmV0dEVUa3otNnZreUw3OFpXcWtOaGFOcnNXazNpM21xLXRRMmFvaVgzanRoMDJtRU4wVU5GTl94WTJMN3pSNS1BaDBOODE2OTdLdGctcS1UQTRF?oc=5","date":"2024-12-19","type":"regulatory","source":"Investing.com","summary":"Citi sees Cipla stock benefiting from $140M Gattx opportunity pending approval - Investing.com","headline":"Citi sees Cipla stock benefiting from $140M Gattx opportunity pending approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOY183aUxzM0ZDTm9KSzZBblRSMlphbmd0d2pyTVNFekV3TVpmcnlfRWVraWQxS0dSYXE5dGFLZC14U19fckk3V1ZxVmNvX0F1WkpuaEg0RmRNUncwQTREMTVaeHVJdVU2Z3NGcFp5ek5xRHpvXzNiS0I5QkNBeWVsSzE1MTlxSzJLdVBDNFFsRW9IUU1LR0pfTXpIcHhFS3dsQ01QSndnR0EyQ0J1R3k1SHFoREFGU1RNTlVMTHEwZ01fQk1uY2FyVGt3aGEtb0VsQXNUbUoxTQ?oc=5","date":"2024-06-21","type":"pipeline","source":"reuters.com","summary":"Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India - reuters.com","headline":"Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPOEpkMmEwRkctaEwtbE04dnp5cUM1bzJPUlJsZUpxczhDaW8wTnBDWXNxSGhIc3dlR1hwSTZzSmFteFNQSVkwRmdXam5WS1hYaWstSzkxOTJRQ3BiTzdrSGhaRHZHdjZFNXdpR1YtOG52VWw5X25zbG5XblBaYkN5aVBiWFg?oc=5","date":"2024-06-20","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India - Yahoo Finance Singapore","headline":"Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPdjBLWXVESkxBSUlEWDF6M3REYUptMWxETUVYenlvTllkYnlwYlBvN1otVkZ2V0l2V2Mzdi1DRVRzbzJvZzNwODRteVRGRHItSFhvTjJUVmdXV2hnSEFwemRISng2U0JhOV96bXhuUEdtaG9UZVNuRWpXMndodjZrN0NhUFNsczBHck0xRlU2VUhtVVNQVVlCLURYZ05Zb3pzU1JzaFIxdE5TalZ4X3ZBZnNxb1RQdUNKU3JjMw?oc=5","date":"2023-09-19","type":"pipeline","source":"reuters.com","summary":"Exclusive: India's Torrent in talks with Apollo to borrow up to $1 bln for Cipla bid, sources say - reuters.com","headline":"Exclusive: India's Torrent in talks with Apollo to borrow up to $1 bln for Cipla bid, sources say","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWGZVeXNVMFBWZGxsWVNCd1NLRWxON3ZWTXk1TFpmQnRxajY1SEFudHZMTDBQSWpINldFVUs0dmNZX00xWGNTR2xxNms3el96dHlHZHk1RVlpb3NzOTdnQ2txRmktMmtkNEFxNGxMSDRWcjFaSUtidDFQYWRZVmw5OS1xMzg2ei1DZzhMNU1SR0FOMnY0akdwWXBNRHRhbzA1QTUwYmMtV3UyMDQwRFZVaVNTVWNlSU03?oc=5","date":"2023-09-18","type":"pipeline","source":"reuters.com","summary":"India's Torrent Pharma in talks with CVC, Bain Capital for Cipla bid- sources - reuters.com","headline":"India's Torrent Pharma in talks with CVC, Bain Capital for Cipla bid- sources","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ3F0RXA3TmJOVkR2czVSLURlUHNuWWVueFZtdzNDNWt6WlFKdk5YNUloQkZFWTRGQUVjbnlMRENzenR3eER2YWgxbnZsdU03aHJWTFJrcEpiSGVySzc2dHlYTG9RTXhDcTdFYXVjdXpYZ0ZZMVpONHlfRzFacThyTmNOTkF4N1hMcUpOY2JGa3lTbWVnSC11X1N1S0VRcmRuTmtCLXNn?oc=5","date":"2020-12-11","type":"patent","source":"BioSpace","summary":"Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation - BioSpace","headline":"Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation","sentiment":"neutral"}],"patents":[{"drugName":"Triomune","drugSlug":"stavudine,-lamivudine,-and-nevirapine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000000},{"drugName":"Asthalin","drugSlug":"salbutamol","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"EU","annualRevenue":50000000000}],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sun Pharma","Dr. Reddy's Laboratories","Aurobindo Pharma"],"therapeuticFocus":["Respiratory","Anti-Retrovirals","Generics"],"financials":null,"yahoo":{"currentPrice":1215.9,"previousClose":1202.4,"fiftyTwoWeekHigh":1673,"fiftyTwoWeekLow":1165.7,"fiftyTwoWeekRange":"1165.7 - 1673.0","fiftyDayAverage":1304.16,"twoHundredDayAverage":1465.2,"beta":0.06,"enterpriseValue":870974488576,"forwardPE":21.9,"priceToBook":2.98,"priceToSales":3.51,"enterpriseToRevenue":3.11,"enterpriseToEbitda":13.68,"pegRatio":0,"ebitda":63687823360,"ebitdaMargin":22.8,"freeCashflow":0,"operatingCashflow":0,"totalDebt":4673699840,"debtToEquity":1.4,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"2.8 - Hold","recommendationKey":"hold","numberOfAnalysts":36,"targetMeanPrice":1434.56,"targetHighPrice":1827,"targetLowPrice":1170,"dividendRate":13,"payoutRatio":0.23,"fiveYearAvgDividendYield":0.48,"exDividendDate":1750982400,"insiderHeldPercent":31,"institutionHeldPercent":40.2,"sharesOutstanding":807782631,"floatShares":563372363,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":56.27,"epsForward":55.59,"revenuePerShare":346.26,"bookValue":407.53,"officers":[{"age":49,"name":"Mr. Achin  Gupta","title":"MD, Global CEO & Additional Director"},{"age":null,"name":"Mr. Pradeep  Bhadauria","title":"President & Global Chief Scientific Officer"},{"age":null,"name":"Mr. Ashish  Adukia","title":"Global Chief Financial Officer"},{"age":null,"name":"Mr. Dinesh Ramniranjan Jain","title":"Senior VP & Head of Corporate Finance"},{"age":null,"name":"Ms. Sneha  Hiranandani B Com","title":"Chief Information Officer"},{"age":null,"name":"Ms. Diksha  Maheshwari","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Rajendra Kumar Chopra","title":"Compliance Officer & Company Secretary"},{"age":null,"name":"Ms. Meera  Vanjari","title":"Global General Counsel"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.cipla.com","phone":"91 22 2482 6000"}}